JAGSONPAL PHARMACEUTICALS
|
JAGSONPAL PHARMACEUTICALS Last 5 Year Financial Ratios History
[Standalone]
| Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 10.20 | 7.20 | 6.51 | 3.00 | 2.75 |
| CEPS(Rs) | 10.66 | 7.78 | 6.93 | 3.44 | 3.14 |
| DPS(Rs) | 5.00 | 4.00 | 1.00 | 0.50 | 0.25 |
| Book NAV/Share(Rs) | 57.30 | 50.68 | 43.55 | 39.39 | 36.89 |
| Tax Rate(%) | 23.23 | 29.23 | 22.01 | 16.40 | 19.85 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 13.28 | 10.32 | 10.15 | 5.38 | 5.60 |
| EBIT Margin(%) | 13.70 | 11.11 | 11.91 | 6.26 | 5.84 |
| Pre Tax Margin(%) | 13.54 | 10.99 | 11.64 | 5.94 | 5.40 |
| PAT Margin (%) | 10.39 | 7.78 | 9.08 | 4.96 | 4.33 |
| Cash Profit Margin (%) | 10.86 | 8.41 | 9.65 | 5.68 | 4.93 |
| Performance Ratios | |||||
| ROA(%) | 14.29 | 11.24 | 10.90 | 5.53 | 5.43 |
| ROE(%) | 18.89 | 15.28 | 15.70 | 7.88 | 7.72 |
| ROCE(%) | 24.15 | 21.23 | 19.43 | 9.46 | 9.80 |
| Asset Turnover(x) | 1.38 | 1.44 | 1.20 | 1.11 | 1.26 |
| Sales/Fixed Asset(x) | 5.63 | 4.10 | 3.18 | 2.80 | 3.07 |
| Working Capital/Sales(x) | 1.88 | 2.95 | 2.35 | 2.57 | 2.40 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.18 | 0.24 | 0.31 | 0.36 | 0.33 |
| Receivable days | 25.87 | 21.26 | 33.13 | 48.57 | 50.22 |
| Inventory Days | 35.78 | 44.76 | 57.34 | 71.38 | 92.03 |
| Payable days | 68.44 | 75.08 | 67.24 | 76.56 | 52.49 |
| Valuation Parameters | |||||
| PER(x) | 28.42 | 43.57 | 12.22 | 5.81 | 9.55 |
| PCE(x) | 27.20 | 40.31 | 11.49 | 5.08 | 8.37 |
| Price/Book(x) | 5.06 | 6.19 | 1.83 | 0.44 | 0.71 |
| Yield(%) | 1.72 | 1.28 | 1.26 | 2.87 | 0.95 |
| EV/Net Sales(x) | 2.72 | 3.66 | 0.82 | 0.07 | 0.20 |
| EV/Core EBITDA(x) | 16.17 | 27.99 | 6.60 | 1.05 | 3.17 |
| EV/EBIT(x) | 18.31 | 29.57 | 6.92 | 1.17 | 3.50 |
| EV/CE(x) | 3.18 | 4.65 | 0.94 | 0.08 | 0.25 |
| M Cap / Sales | 3.21 | 3.78 | 1.11 | 0.29 | 0.41 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 8.79 | 15.77 | 18.53 | -4.95 | 31.84 |
| Core EBITDA Growth(%) | 40.18 | 21.22 | 112.25 | 2.74 | 201.07 |
| EBIT Growth(%) | 30.80 | 20.29 | 125.46 | 1.85 | 188.87 |
| PAT Growth(%) | 41.72 | 10.53 | 116.73 | 9.07 | 162.47 |
| EPS Growth(%) | 41.72 | 10.53 | 116.73 | 9.08 | 162.47 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | - | - | 0.06 | 0.06 | 0.04 |
| Current Ratio(x) | 4.89 | 3.40 | 2.98 | 2.79 | 3.46 |
| Quick Ratio(x) | 4.31 | 2.53 | 2.25 | 1.94 | 2.30 |
| Interest Cover(x) | 85.28 | 94.48 | 43.59 | 19.31 | 13.08 |
| Total Debt/Mcap(x) | - | - | 0.03 | 0.14 | 0.05 |
Compare Financial Ratios of peers of JAGSONPAL PHARMACEUTICALS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| JAGSONPAL PHARMACEUTICALS | ₹887.0 Cr | -8.1% | 7.6% | -4.1% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹365,071.0 Cr | 0.2% | -6.1% | 55.7% | Stock Analytics | |
| CIPLA | ₹111,808.0 Cr | -2.5% | -5.1% | 48.6% | Stock Analytics | |
| DIVIS LABORATORIES | ₹104,300.0 Cr | -0.9% | 5% | 19.2% | Stock Analytics | |
| ZYDUS LIFESCIENCES | ₹101,202.0 Cr | 1.8% | 2.2% | 88.6% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹101,035.0 Cr | -3.7% | -1.4% | 26% | Stock Analytics | |
JAGSONPAL PHARMACEUTICALS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| JAGSONPAL PHARMACEUTICALS | -8.1% |
7.6% |
-4.1% |
| SENSEX | -1.4% |
-0.6% |
20.1% |
You may also like the below Video Courses
